Maze Therapeutics, Inc. (MAZE): Cash & Equivalents
$189.25M
As of 2025-12-31
$202.64M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $189.25M | -3.8% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $196.81M | n/a | 2026-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $189.25M | -3.8% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $323.53M | +81.9% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $51.69M | -31.3% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $71.87M | -43.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $88.33M | +6.4% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $209.86M | +24.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗